Effect of toripalimab plus cetuximab combined with radiotherapy on
patient with locally advanced high-grade parotid mucoepidermoid
carcinoma
Abstract
Background: Mucoepidermoid carcinoma (MEC) is the most common malignant
tumor of the salivary glands, accounting for approximately one-third of
all salivary gland tumors. Based on the proportion of epidermoid and
mucous cells, MEC is classified into three grades. High-grade MEC, an
extremely rare malignancy, has a higher proportion of epidermoid cells
and a poorer prognosis. Currently, there has been no standard treatment
for patients with positive surgical margins after parotidectomy. Case
description: This case report describes the successful treatment of a
patient with high-grade parotid MEC and positive surgical margins using
toripalimab plus cetuximab combined with radiotherapy, who achieved
complete response one month after the completion of treatment.
Conclusion: We report a case in which a patient with locally advanced
high-grade parotid MEC with R2 resection achieved a complete response
after postoperative adjuvant radiotherapy combined with toripalimab and
cetuximab.